Nanobiotix S.A. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NBTX Nasdaq 2830 www.nanobiotix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nanobiotix S.A.

Nanobiotix (NBTX) Provides Update on Operational Progress - Jun 22nd, 2026 6:47 am
Voting Rights and Shares Capital of the Company - Jun 5th, 2026 2:15 pm
Nanobiotix Provides First Quarter 2026 Operational and Financial Update - Jun 2nd, 2026 2:30 pm
Nanobiotix Joins the Euronext Tech Leaders Index - Jun 2nd, 2026 12:30 am
Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally - May 30th, 2026 4:04 pm
NANOBIOTIX Announces Closing of Global Offering - May 26th, 2026 2:59 pm
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million - May 22nd, 2026 2:15 pm
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering - May 21st, 2026 8:57 am
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris - May 21st, 2026 7:30 am
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Uncertainty Surrounding US-Iran Talks - May 21st, 2026 7:18 am
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris - May 21st, 2026 12:30 am
Nanobiotix Announces Launch of Global Follow-On Offering - May 20th, 2026 4:19 pm
How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer - May 20th, 2026 6:00 am
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - May 17th, 2026 8:15 am
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study - May 4th, 2026 3:29 pm
Assessing Nanobiotix (ENXTPA:NANO) Valuation After Strong Recent Share Price Momentum - Apr 27th, 2026 5:08 am
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology - Apr 20th, 2026 12:30 am
Nanobiotix H2 Earnings Call Highlights - Apr 1st, 2026 9:20 am
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results - Mar 31st, 2026 2:15 pm
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - Mar 30th, 2026 12:30 am